SCHEMBL6698534

SCHEMBL6698534

c1ccc(-c2nnc(-c3ccccn3)o2)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 12/20 0.65
NPC1 O15118 11/20 0.65
SMN1; SMN2 Q16637 7/20 0.65
ATAD2 Q6PL18 1/20 0.60
TP53 P04637 4/20 0.54
PKM P14618 3/20 0.54
HPGD P15428 7/20 0.53
POLB P06746 1/20 0.53
NFKB1 P19838 1/20 0.53
NFKB2 Q00653 1/20 0.53
RELA Q04206 1/20 0.53
MEN1 O00255 1/20 0.53
KMT2A Q03164 1/20 0.53
ACHE P22303 2/20 0.53
GUSB P08236 1/20 0.52
KDM4E B2RXH2 6/20 0.52
ALDH1A1 P00352 6/20 0.52
HSD17B10 Q99714 4/20 0.52
MAPT P10636 2/20 0.52
GLA P06280 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10553462 0.90 KDM4E (0.59) RAB9ANPC1SMN1; SMN2TP53PKM
SCHEMBL27845508 0.89 NPC1 (0.67) RAB9ANPC1SMN1; SMN2ATAD2TP53
SCHEMBL29244073 0.88 SMN1; SMN2 (0.58) RAB9ANPC1SMN1; SMN2ATAD2TP53
SCHEMBL15272148 0.86 RAB9A (0.57) RAB9ANPC1SMN1; SMN2TP53PKM
SCHEMBL21251531 0.86 NPC1 (0.66) RAB9ANPC1SMN1; SMN2TP53PKM
SCHEMBL13134532 0.83 RAB9A (0.53) RAB9ANPC1SMN1; SMN2ATAD2TP53
SCHEMBL2197485 0.82 SMN1; SMN2 (0.60) RAB9ANPC1SMN1; SMN2ATAD2TP53
SCHEMBL14395153 0.82 HPGD (0.69) RAB9ANPC1SMN1; SMN2TP53PKM
SCHEMBL12419577 0.82 GUSB (0.48) RAB9ANPC1SMN1; SMN2ATAD2TP53
SCHEMBL22734893 0.82 RAB9A (0.54) RAB9ANPC1SMN1; SMN2ATAD2TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10749128-B2 Depositable ion organic function material and use thereof in organic electroluminescent device KUNSHAN GO-VISIONOX OPTO-ELECTRONICS CO., LTD. (CN) 2020-08-18 US disclosed
EP-3318617-B1 DEPOSITABLE ION ORGANIC FUNCTION MATERIAL AND USE THEREOF IN ORGANIC ELECTROLUMINESCENT DEVICE KUNSHAN GOVISIONOX OPTOELECTRONICS CO LTD (CN) 2019-08-14 EP disclosed
US-20040248950-A1 Apo ai expression accelerating agent SHIONOGI & CO., LTD. (JP) 2004-12-09 US disclosed
EP-1419770-A1 APO AI EXPRESSION ACCELERATING AGENT SHIONOGI & CO., LTD. (JP) 2004-05-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040248950-A1 Apo ai expression accelerating agent APOB, APOL1, NR1H2 RAB9A 3759/4885NPC1 129/4885SMN1; SMN2 1789/4885
US-10749128-B2 Depositable ion organic function material and use thereof in organic electroluminescent device OCIAD1, OCIAD2, OXA1L RAB9A 2721/4885NPC1 905/4885SMN1; SMN2 2962/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.